dc.contributor.author | Tenececi, N | |
dc.contributor.author | Topuz, E | |
dc.contributor.author | Kizir, A | |
dc.contributor.author | Yoney, A | |
dc.contributor.author | Kaytan, E | |
dc.contributor.author | Oral, EN | |
dc.contributor.author | Bavbek, S | |
dc.date.accessioned | 2021-03-05T17:32:39Z | |
dc.date.available | 2021-03-05T17:32:39Z | |
dc.date.issued | 1999 | |
dc.identifier.citation | Oral E., Bavbek S., Kizir A., Tenececi N., Yoney A., Kaytan E., Topuz E., "Preliminary analysis of a phase II study of Paclitaxel and CHART in locally advanced non-small cell lung cancer", LUNG CANCER, cilt.25, ss.191-198, 1999 | |
dc.identifier.issn | 0169-5002 | |
dc.identifier.other | av_c6147d30-d4ad-4d19-a006-55bb1121c72a | |
dc.identifier.other | vv_1032021 | |
dc.identifier.uri | http://hdl.handle.net/20.500.12627/131331 | |
dc.identifier.uri | https://doi.org/10.1016/s0169-5002(99)00068-9 | |
dc.description.abstract | Paclitaxel (Taxol(R); Bristol-Myers Squibb) is one of the most active single agents for non-small cell lung cancer (NSCLC), and ideal in combination with radiation therapy. We designed a phase II study to determine the efficacy and toxicity of continuous hyperfractionated accelerated radiotherapy (CHART) and concurrent weekly Paclitaxel (T) in good performance status patients with unresectable stage III A and B NSCLC. T (60 mg/m(2)) was given as a 3-h infusion on days 1, 8, 15, 22, 29 and 36; CHART was started on day 15 with 150 cGy/fraction given three times a day for a total dose of 54 Gy in 12 days with no weekend break. Twenty patients were evaluable for acute toxicity. The major acute toxicities were esophagitis and pulmonary toxicity; 70% of the patients experienced grade 2-3 esophagitis and 50% experienced grade greater than or equal to 3 pulmonary toxicity. Grade 3 anemia developed in only one patient. Of the 17 patients evaluable for late toxicity, 12% of the patients had grade 3 pulmonary toxicity, one patient developed grade 4 esophagitis. Nineteen patients were evaluable response. The overall response rate was 84% (95% confidence interval, 60-97). CHART with concurrent weekly T seems to be an effective regimen, but tolerability needs to be documented with a larger number of patients and longer follow-up. (C) 1999 Elsevier Science Ireland Ltd. All rights reserved. | |
dc.language.iso | eng | |
dc.subject | Göğüs Hastalıkları ve Allerji | |
dc.subject | İç Hastalıkları | |
dc.subject | Sağlık Bilimleri | |
dc.subject | Onkoloji | |
dc.subject | Dahili Tıp Bilimleri | |
dc.subject | Tıp | |
dc.subject | SOLUNUM SİSTEMİ | |
dc.subject | Klinik Tıp (MED) | |
dc.subject | Klinik Tıp | |
dc.subject | ONKOLOJİ | |
dc.title | Preliminary analysis of a phase II study of Paclitaxel and CHART in locally advanced non-small cell lung cancer | |
dc.type | Makale | |
dc.relation.journal | LUNG CANCER | |
dc.contributor.department | , , | |
dc.identifier.volume | 25 | |
dc.identifier.issue | 3 | |
dc.identifier.startpage | 191 | |
dc.identifier.endpage | 198 | |
dc.contributor.firstauthorID | 123939 | |